HomeCompareMLPH vs MRK

MLPH vs MRK: Dividend Comparison 2026

MLPH yields 250000.00% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLPH wins by $4.567699004441311e+30M in total portfolio value
10 years
MLPH
MLPH
● Live price
250000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.567699004441311e+30M
Annual income
$4,564,107,688,187,857,300,000,000,000,000,000,000.00
Full MLPH calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — MLPH vs MRK

📍 MLPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLPHMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLPH + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLPH pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLPH
Annual income on $10K today (after 15% tax)
$21,250,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,879,491,534,959,678,500,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MLPH beats the other by $3,879,491,534,959,678,500,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLPH + MRK for your $10,000?

MLPH: 50%MRK: 50%
100% MRK50/50100% MLPH
Portfolio after 10yr
$2.2838495022206556e+30M
Annual income
$2,282,053,844,093,928,700,000,000,000,000,000,000.00/yr
Blended yield
99.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MLPH
No analyst data
Altman Z
-637.0
Piotroski
0/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLPH buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLPHMRK
Forward yield250000.00%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4.567699004441311e+30M$57.7K
Annual income after 10y$4,564,107,688,187,857,300,000,000,000,000,000,000.00$10,113.78
Total dividends collected$4.567463897060879e+30M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MLPH vs MRK ($10,000, DRIP)

YearMLPH PortfolioMLPH Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$25,010,700$25,000,000.00$11,213$373.04+$25.00MMLPH
2$58,462,976,402$58,436,214,953.27$12,667$512.06+$58462.96MMLPH
3$127,722,124,784,416$127,659,569,399,665.92$14,439$708.14+$127722124.77MMLPH
4$260,784,910,907,288,130$260,648,248,233,768,800.00$16,640$988.16+$260784910907.27MMLPH
5$497,657,939,618,196,950,000$497,378,899,763,526,240,000.00$19,432$1,394.07+$497657939618196.94MMLPH
6$887,590,576,640,622,200,000,000$887,058,082,645,230,600,000,000.00$23,057$1,992.90+$887590576640622208.00MMLPH
7$1,479,547,418,610,237,200,000,000,000$1,478,597,696,693,231,600,000,000,000.00$27,889$2,894.79+$1.4795474186102372e+21MMLPH
8$2,305,052,548,351,757,200,000,000,000,000$2,303,469,432,613,844,500,000,000,000,000.00$34,518$4,286.29+$2.3050525483517572e+24MMLPH
9$3,356,370,330,330,650,300,000,000,000,000,000$3,353,903,924,103,914,000,000,000,000,000,000.00$43,912$6,494.35+$3.3563703303306504e+27MMLPH
10$4,567,699,004,441,311,000,000,000,000,000,000,000$4,564,107,688,187,857,300,000,000,000,000,000,000.00$57,714$10,113.78+$4.567699004441311e+30MMLPH

MLPH vs MRK: Complete Analysis 2026

MLPHStock

Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in various dosage forms, formulations, line extensions, and package configurations. The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe. It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient. The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited.

Full MLPH Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MLPH vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLPH vs SCHDMLPH vs JEPIMLPH vs OMLPH vs KOMLPH vs MAINMLPH vs JNJMLPH vs ABBVMLPH vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.